VP Digital Products & Strategy | Healthcare | Digital Transformation | B2B B2B2C DTC
I've been looking forward to the reports from Peterson Health Technology Institute (PHTI), and this report does not disappoint! Whether you agree or disagree with the findings, buyers should look at their performance guarantees. Peterson Health Technology Institute (PHTI) recommends that buyers "Refocus performance guarantees on patients with the highest HbA1c — As discussed above, people with higher starting HbA1c who are newly starting insulin are likely to experience greater benefits from the use of these technologies. Populations that have high HbA1c are also more likely to be low-income and disproportionately Black and Hispanic. While some contracts with digital solutions include performance guarantees, they are often not focused on specific subpopulations. Purchasers should define meaningful clinical and economic impact targets that emphasize success in these important subpopulations who may be more likely to benefit from the solution."
A searing analysis published today by Peterson Health Technology Institute (PHTI) that I expect will create ripples across the industry finds that "digital diabetes management solutions ... do not deliver meaningful clinical benefits, and they increase healthcare spending relative to usual care." Tools assessed for the analysis include those from companies such as Omada Health, Vida Health, Glooko, Onduo by Verily and Teladoc's Livongo.
